Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Pelacarsen trial shows no reduction in heart attacks, strokes

8 November 2026 · By · Wire by Fusion42

Published

8 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at qz.com →

◆ Verified

Fusion42 · 8 November 2026 · Fusion42 review

Novartis' experimental drug pelacarsen failed to reduce heart attacks, strokes, or cardiovascular death in a major clinical trial despite lowering lipoprotein(a) levels, leading Novartis to halt further studies of the drug.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 7 Nov 2026 and 8 Nov 2026.

◆ ◆ The Wire takeaway

Your biotech startup must prepare for a tougher market as a leading cholesterol drug failed a pivotal trial, shifting investor and regulatory scrutiny to deeper proof of patient outcomes over biomarker changes.

◆ Coverage

4 sources · first reported 7 Nov 2026 · latest 8 Nov 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialcardiovasculardrug-failurebiotechnovartis